Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Effect of the new centrally acting antihypertensive agent rilmenidine on endothelial and platelet function in essential hypertension

Journal of Human Hypertension volume 16, pages 549–555 (2002)Cite this article

Abstract

The aim of the study was to investigate the effect of therapy by rilmenidine on endothelial and platelet function in 23 patients with the early stages of untreated essential hypertension. The measurements were carried out before therapy, after 1 week of placebo administration, after 1 week, after 1 month and after 3 months of therapy. After 1 week of therapy both systolic (SBP) and diastolic blood pressure (DBP) were reduced (P < 0.001) all over the study period. Plasma thrombomodulin (TM) and von Willebrand factor (vWF) as indicators of endothelial dysfunction, and plasma β-thromboglobulin (βTG) as an indicator of in vivo platelet activation, were investigated. Fibrinogen as a risk factor for vascular changes was also assayed. Platelet aggregation without stimulation (spontaneous, SPA) and induced by adrenaline (APA) was measured. A decrease of plasma vWF level after 1 month (P < 0.05) and after 3 months (P < 0.05) of therapy was observed. We failed to find any changes of plasma TM and fibrinogen level. A reduction of platelet aggregation was evident after 1 week (SPA and APA, P < 0.05, respectively) but mainly after 1 month (SPA P < 0.01, APA P < 0.05) and after 3 months of therapy (SPA and APA, P < 0.01, respectively). It was accompanied by a decrease of plasma ßTG level after 3 months of therapy (P < 0.05). The vasculoprotective and antiplatelet effect of rilmenidine may be important in terms of the favourable role of antihypertensive drugs in cardiovascular morbidity.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Spencer CGC, Beevers DG, Lip GYH . Haemorheological, endothelial and platelet function in subjects with hypertension: relationship to cardiovascular risk and influence of antihypertensive treatment J Hum Hypertens 2001; 15 (Suppl 1): S39–S42

    Article  PubMed  Google Scholar 

  2. Lip GYH, Beevers DG . Abnormalities of rheology and coagulation in hypertension J Hum Hypertens 1994; 8: 693–702

    CAS  PubMed  Google Scholar 

  3. Blann AD, Naqvi T, Waite M, McCollum CN . Von Willebrand factor and endothelial damage in essential hypertension J Hum Hypertens 1993; 7: 107–111

    CAS  PubMed  Google Scholar 

  4. Kloczko J et al. Von Willebrand factor antigen and fibronectin in essential hypertension Thromb Res 1995; 79: 331–336

    Article  CAS  PubMed  Google Scholar 

  5. Blann A, Seigneur M . Soluble markers of endothelial cell function Clin Hemorheol Microcirc 1997; 17: 3–11

    CAS  PubMed  Google Scholar 

  6. Lee AJ, Lowe GDO, Woodward M, Tunstall-Pedoe H . Fibrinogen in relation to personal history of prevalent hypertension, diabetes, stroke, intermittent claudication, coronary heart disease, and family history: the Scottish Heart Health Study Br Heart J 1993; 69: 338–342

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Remko M, Walsh OA, Richards WG . Molecular structure and gas-phase reactivity of clonidine and rilmenidine: two layered ONIOM calculations Phys Chem Chem Phys 2001; 3: 901–907

    Article  CAS  Google Scholar 

  8. Bousquet P, Dontenwill M, Greney H, Feldman J . Imidazoline receptors in cardiovascular and metabolic diseases J Cardiovasc Pharmacol 2000; 35 (Suppl 4): S21–S25

    Article  CAS  PubMed  Google Scholar 

  9. Safar ME . Rilmenidine: a novel antihypertensive agent Am J Med 1989; 87 (Suppl 3C): 24S–29S

    Article  CAS  PubMed  Google Scholar 

  10. Okrucká-Remková A, Pechán J, Kratochvíl'ová H . Effects of the angiotensin-converting enzyme (ACE) inhibitor perindopril on endothelial and platelet functions in essential hypertension Platelets 1998; 9: 63–67

    Article  Google Scholar 

  11. Trifiletti A et al. Effects of medium-term antihypertensive therapy on haemostatic parameters inpatients with essential hypertension Haemostasis 1997; 27: 35–38

    CAS  PubMed  Google Scholar 

  12. Messerli F . Moxonidine: a new and versatile antihypertensive J Cardiovasc Pharmacol 2000; 35 (Suppl 4): S53–S56

    Article  CAS  PubMed  Google Scholar 

  13. Boneu B, Abbal M, Plante J, Bierme R . Letter: Factor-VIII complex and endothelial damage Lancet 1975; i: 1430

    Article  Google Scholar 

  14. Kario K et al. Factor VII hyperactivity and endothelial cell damage are found in elderly hypertensives only when concomitant with microalbuminuria Arterioscler Thromb Vasc Biol 1996; 16: 455–461

    Article  CAS  PubMed  Google Scholar 

  15. Verhaar MC et al. Progressive vascular damage in hypertension is associated with increased levels of circulating P-selectin J Hypertens 1998; 16: 45–50

    Article  CAS  PubMed  Google Scholar 

  16. Pedrinelli R et al. Microalbuminuria and endothelial dysfunction in essential hypertension Lancet 1994; 344: 14–18

    Article  CAS  PubMed  Google Scholar 

  17. Ferri C et al. Clustering of endothelial markers of vascular damage in human salt-sensitive hypertension: influence of dietary sodium load and depletion Hypertension 1998; 32: 862–868

    Article  CAS  PubMed  Google Scholar 

  18. Seigneur M et al. Levels of plasma thrombomodulin are increased in atheromatous arterial disease Thromb Res 1993; 71: 423–431

    Article  CAS  PubMed  Google Scholar 

  19. Seigneur M, Dufourcq P, Conri C . Plasma thrombomodulin – new approach of endothelial damage Int Angiol 1993; 12: 85–93

    Google Scholar 

  20. Remkova A, Kovacova E, Prikazska M, Kratochvilova H . Thrombomodulin as a marker of endothelium damage in some clinical conditions Eur J Int Med 2000; 11: 79–84

    Article  CAS  Google Scholar 

  21. Cacoub P et al. Plasma levels of thrombomodulin in pulmonary hypertension Am J Med 1996; 101: 160–164

    Article  CAS  PubMed  Google Scholar 

  22. Makris TK et al. Fibrinolytic/hemostatic variables in arterial hypertension: response to treatment with irbesartan or atenolol Am J Hypertens 2000; 13: 783–788

    Article  CAS  PubMed  Google Scholar 

  23. Krespi PG et al. Moxonidine effect on microalbuminuria, thrombomodulin, and plasminogen activator inhibitor-1 levels inpatients with essential hypertension Cardiovasc Drugs Ther 1998; 12: 463–467

    Article  CAS  PubMed  Google Scholar 

  24. De Luca N et al. Haemodynamic and metabolic effects of rilmenidine in hypertensivepatients with metabolic syndrome X. A double-blind parallel study versus amlodipine J Hypertens 2000; 18: 1515–1522

    Article  CAS  PubMed  Google Scholar 

  25. Piletz JE, Andorn AC, Unnerstall JR, Halaris A . Binding of [3H]-p-aminoclonidine to α2-adrenoceptor states plus a non-adrenergic site on human platelet plasma membranes Biochem Pharmacol 1991; 42: 569–584

    Article  CAS  PubMed  Google Scholar 

  26. Piletz JE, Sletten K . Nonadrenergic imidazoline binding sites on human platelets J Pharmacol Exp Ther 1993; 267: 1493–1502

    CAS  PubMed  Google Scholar 

  27. Wiest SA, Steinberg MI . Effect of the imidazoline receptor ligand moxonidine on human platelet aggregation Ann NY Acad Sci 1995; 763: 606–609

    Article  CAS  PubMed  Google Scholar 

  28. Ernsberger P . Pharmacology of moxonidine: an I1-imidazoline receptor agonist J Cardiovasc Pharmacol 2000; 35 (Suppl 4): S27–S41

    Article  CAS  PubMed  Google Scholar 

  29. Esler M, Kaye D . Sympatethic nervous system activation in essential hypertension, cardiac failure and psychosomatic heart disease J Cardiovasc Pharmacol 2000; 35 (Suppl 4): S1–S7

    Article  CAS  PubMed  Google Scholar 

  30. Mancia G, Di Rienzo M, Parati G, Grassi G . Sympathetic activity, blood pressure variability and end organ damage in hypertension J Hum Hypertens 1997; 11 (Suppl 1): S3–S8

    PubMed  Google Scholar 

Download references

Acknowledgements

The authors thank Mrs Viera Tokárová, Mrs Eva Csizmáziová and Mrs Helena Mackovýchová for their technical assistance. This research was supported by grants from the Slovak Ministry of Education (Grant No 1/7361/20 and No 1/8289/01).

Author information

Authors and Affiliations

  1. 1st Department of Internal Medicine, School of Medicine, Comenius University, Bratislava, Slovak Republic

    A Remková & H Kratochvíl'ová

Authors
  1. A Remková
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H Kratochvíl'ová
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A Remková.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Remková, A., Kratochvíl'ová, H. Effect of the new centrally acting antihypertensive agent rilmenidine on endothelial and platelet function in essential hypertension. J Hum Hypertens 16, 549–555 (2002). https://doi.org/10.1038/sj.jhh.1001427

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.jhh.1001427

Keywords

This article is cited by

Search

Advanced search

Quick links